What is DRMA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for DRMA?

P/E (TTM) is n/a and 52-week range is $0.95 to $5.18 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s DRMA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for DRMA?

The company profile lists net income (TTM) near $-18M, EPS (TTM) near $-4.51 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Dermata Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 4M shares outstanding, ISIN US2498455045 when available from company profile and filing metadata.

Dermata Therapeutics Inc

$DRMA

Health Care · Biotechnology

IR Run Scenarios

$1.02

-4.67%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The company went IPO on 2021-08-13. The firm is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.

Employees

Website

www.dermatarx.com/

IPO

2021-08-13

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)